Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2023-12-01 Board/Management Inform…
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the ....
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the appointment of a senior management personnel, Mr. Venkat Natarajan, as Lead - Market Access effective January 2, 2024. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in senior management. The content includes details about the appointment, the individual's profile, and the effective date. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of a management change rather than a report or financial filing. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused solely on this appointment, reinforcing this classification.
2023-12-01 English
Updates
Regulatory Filings
2023-11-28 English
AstraZeneca Pharma India Limited receives permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drug Standard Control Organisation ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about AstraZeneca Pharma India Limited receiving permission from the Central Drugs Standard Control Organisation to import pharmaceutical formulations of a new drug (Olaparib) for an additional indication. The content is an official notification about regulatory approval related to the company's product, not a financial report, earnings release, or management discussion. The document length is short (1920 characters), and it serves as an announcement to the stock exchanges rather than a detailed report or presentation. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance-related notifications that do not fit other specific categories.
2023-11-21 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about AstraZeneca Pharma India Limited receiving permission from the Central Drugs Standard Control Organisation to import pharmaceutical formulations of a new drug for sale or distribution. The content is an official notification about regulatory approval related to a pharmaceutical product, not a financial report, earnings release, or management discussion. The document length is short (1920 characters), and it serves as an announcement of a regulatory event rather than a detailed report or financial filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-11-21 English
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 95% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges. It announces AstraZeneca Pharma India Limited's intention to exit a manufacturing site and related strategic plans. The content is an official announcement about a significant operational change, not a financial report, audit, or meeting material. It does not contain financial data, voting results, or executive changes. It fits the category of a regulatory announcement about a material event affecting the company, which aligns with Regulatory Filings (RNS). The document length is short and is an announcement rather than a detailed report or presentation.
2023-11-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces AstraZeneca Pharma India Limited's intention to exit a manufacturing site and put it up for sale, which is a material event affecting the company. The document is short (1716 characters) and serves as an announcement rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. Therefore, it fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-11-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.